Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07264413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bleeding Reduction in Grade II-III Haemorrhoids Through Embolization Treatment

Study acronym: BRIGHT
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Apr 2026 to Aug 2026v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BRIGHT is a Europe-wide study that will follow up to 250 adults with bleeding symptoms from haemmorhoids (Grade II-III categories). It aims to understand how well a minimally invasive procedure called haemorrhoid artery embolization (HAE) works in everyday clinical practice, which is a technique that blocks the blood vessels feeding the haemorrhoids. As this technique does not require major surgery, HAE offers several benefits such as less trauma, quicker recovery, and the use of only local anaesthesia.
Trial Details
NCT Number NCT07264413
Lead Sponsor Cardiovascular and Interventional Radiological Society of Europe
Collaborators: Medtronic, Cook Group Incorporated
Conditions
(from sponsor)		 Hemorrhoid, Hemorrhoid Bleeding
Related terms Hemorrhoids
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov